DERMATA THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
DERMATA THERAPEUTICS, INC. (DRMA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $41.78 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- DERMATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $41.78K, a 6.49% increase year-over-year.
- DERMATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $43.28K, a 16.37% increase year-over-year.
- DERMATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $37.84K, a 80.26% increase year-over-year.
- DERMATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $39.23K, a 100.09% increase year-over-year.
- DERMATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $143.73K, a 78.14% decline from fiscal 2024.
- DERMATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $657.65K, a 25.97% increase from fiscal 2023.
- DERMATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $522.08K, a 51.75% decline from fiscal 2022.
- DERMATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.08M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.78K 10-Q · filed 2026-08-11 | $85.06K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $43.28K 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $143.73K 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $37.84K 10-Q · filed 2025-11-14 | $77.07K derived: sum of 2 quarters · filed 2026-08-11 | $114.26K derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $39.23K 10-Q · filed 2026-08-11 | $76.42K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $37.19K 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $657.65K 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $20.99K 10-Q · filed 2025-11-14 | $40.60K derived: sum of 2 quarters · filed 2025-11-14 | $627.83K derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $19.61K 10-Q · filed 2025-11-14 | $606.84K derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $587.23K 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $522.08K 10-K · filed 2025-03-17 | |||
| 2023-09-30 | $131.18K 10-Q · filed 2024-11-13 | $262.35K derived: sum of 2 quarters · filed 2024-11-13 | $393.61K derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $131.18K 10-Q · filed 2024-11-13 | $262.44K derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $131.26K 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $1.08M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $179.36K 10-Q · filed 2023-11-09 | $385.31K derived: sum of 2 quarters · filed 2023-11-09 | $916.87K derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $205.95K 10-Q · filed 2023-11-09 | $737.51K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $531.57K 10-Q · filed 2023-11-09 | |||
| 2021-09-30 | $142.66K 10-Q · filed 2022-11-10 | $256.64K derived: sum of 2 quarters · filed 2022-11-10 | $1.42M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $113.99K 10-Q · filed 2022-11-10 | $1.27M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $1.16M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |